Yoshikazu Yonemitsu
Corporate Officer/Principal bei Kyushu University
Profil
Yoshikazu Yonemitsu is the founder of GAIA BioMedicine Inc. which was founded in 2015.
Currently, he is a Professor at Kyushu University since 1990.
Dr. Yonemitsu's former job was as an Outside Director at tella, Inc.
Aktive Positionen von Yoshikazu Yonemitsu
| Unternehmen | Position | Beginn |
|---|---|---|
| Kyushu University | Corporate Officer/Principal | 01.04.1990 |
Ehemalige bekannte Positionen von Yoshikazu Yonemitsu
| Unternehmen | Position | Ende |
|---|---|---|
GAIA BioMedicine Inc.
 GAIA BioMedicine Inc. Miscellaneous Commercial ServicesCommercial Services GAIA BioMedicine Inc. engages in the development of regenerative medicine and other product development. Its products include medicines for cell and gene therapy. It also offers services on drug screening and advance medical support. The company was founded by Yoshikazu Yonemitsu in October 2015 and is headquartered in Fukuoka, Japan. | Gründer | - |
| TELLA, INC. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
GAIA BioMedicine Inc.
GAIA BioMedicine Inc. Miscellaneous Commercial ServicesCommercial Services GAIA BioMedicine Inc. engages in the development of regenerative medicine and other product development. Its products include medicines for cell and gene therapy. It also offers services on drug screening and advance medical support. The company was founded by Yoshikazu Yonemitsu in October 2015 and is headquartered in Fukuoka, Japan. | Commercial Services |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
